EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA (K23M)

描述（由申请人提供）：骨髓瘤和其他b细胞恶性肿瘤的新治疗策略的发展需要临床研究人员和基础科学家之间的合作努力。显然，我们需要具备病人护理、临床试验设计和基本科学原理方面的技能的个人，他们可以在这些和其他形式的癌症的新治疗方法的构思、开发和评估方面弥合实验室和床边之间的差距。作为该项目的首席研究员，Niesvizky博士致力于进一步的研究活动，并为他的职业发展接受进一步的指导培训，以填补这一长期角色。为了获得必要的技能，战略是遵循教育和研究路径，包括：

DESCRIPTION (provided by applicant): Development of novel therapeutic strategies in myeloma and other B-cell malignancies requires collaborative efforts between clinical researchers and basic scientists. There is a clear need for individuals with skills in patients care, clinical trial design, and basic science principles who can bridge the gap between the bench and the bedside in the conception, development and evaluation of new treatment in these and other forms of cancer. As the principal investigator in this project, Dr Niesvizky is dedicated to further his research activities and undergo further mentored training for his career development to fill this long-term role. In order to attain the necessary skills, the strategy is to follow an educational and research path including: 1) Development and execution of a translational study to evaluate the effect of selected promising agents in the treatment of multiple myeloma under the tutoring of Drs. Bergsagel and Chen-Kiang. 2) Didactic and mentored training in clinical trial design with Dr Scott Wadler, as well as through several institutional resources including the General Clinical Research Center and the Weill Graduate School of Medical Sciences of Cornell University. 3)Development and execution of investigator-initiated clinical trials for myeloma using novel agents and combinations. Dr Niesvizky's research is focused in drug development. Following this five-year comprehensive program, he will attain the independent clinical research skills to work with basic science collaborators to lead a translational research program in drug development and other novel treatments for myeloma. It is expected that this work will significantly contribute to the care of patients with this disease and other B-cell malignancies.